CTLA4 and neoplasm: Both are now used widely for many other cancers and are often used as dual therapy with ipilimumab, a Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) inhibitor, due to their synergistic effects in targeting tumor cells (Wei et al., 2018).